J. Goldman & Co LP Acquires New Shares in Pacira BioSciences, Inc. $PCRX

J. Goldman & Co LP bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 22,078 shares of the company’s stock, valued at approximately $560,000. J. Goldman & Co LP owned 0.06% of Pacira BioSciences at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in shares of Pacira BioSciences by 15.1% in the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after purchasing an additional 492 shares in the last quarter. Inspire Investing LLC lifted its holdings in Pacira BioSciences by 3.2% during the 4th quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock worth $465,000 after purchasing an additional 556 shares in the last quarter. State of Wyoming lifted its holdings in Pacira BioSciences by 7.0% during the 4th quarter. State of Wyoming now owns 11,155 shares of the company’s stock worth $289,000 after purchasing an additional 728 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Pacira BioSciences by 2.6% during the 4th quarter. Franklin Resources Inc. now owns 33,860 shares of the company’s stock worth $876,000 after purchasing an additional 846 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Pacira BioSciences by 10.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 11,746 shares of the company’s stock worth $268,000 after purchasing an additional 1,142 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Truist Financial assumed coverage on Pacira BioSciences in a report on Monday, August 17th. They set a “buy” rating and a $30.00 target price for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, August 17th. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Finally, Royal Bank Of Canada upped their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.20.

Insider Transactions at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the transaction, the insider directly owned 216,384 shares in the company, valued at approximately $5,026,600.32. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president directly owned 62,284 shares in the company, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $25.90 on Thursday. Pacira BioSciences, Inc. has a 52-week low of $18.80 and a 52-week high of $27.66. The stock has a fifty day moving average of $25.05 and a 200 day moving average of $23.78. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of 74.00 and a beta of 0.27.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The business had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. During the same period in the prior year, the company earned $0.74 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, research analysts expect that Pacira BioSciences, Inc. will post 1.98 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.